Irinotecan sucrosofate: all 72 studies that test it
Page 1 of 1. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingNCT07521605Phase 2
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic CancerNot yet recruitingNCT07314385Phase 1
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Phase 2
- Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingNCT07051785Phase 2
- PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer TreatmentNot yet recruitingNCT07028424Phase 2
- Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsRecruitingNCT06835387Phase 2
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingNCT06827717Phase 2
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingNCT06821997Phase 2
- Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic CancerNot yet recruitingNCT06700603Phase 2
- Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTCNot yet recruitingNCT06699459Phase 2
- Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPCRecruitingNCT06657690Phase 2
- Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic CancerNot yet recruitingNCT06513455Phase 1/2
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06512428Phase 2
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
- Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal CancerRecruitingNCT06405139Phase 2
- Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingNCT06370754Phase 1/2
- Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic CancerRecruitingNCT06361316Not applicable
- Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
- Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNCT06258642Not applicable
- Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal CancerRecruitingNCT06225622Phase 1
- Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOXNot yet recruitingNCT06210360Phase 2
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingNCT05927857Phase 1/2
- Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETEnrolling by invitationNCT05385861Phase 1/2
- Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic AdenocarcinomaRecruitingNCT05363007Phase 2
- Folfox+Irinotecan+Chemort In Esophageal CancerRecruitingNCT04656041Phase 2
- Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the PancreasRecruitingNCT04617457Phase 2
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsRecruitingNCT02013336Phase 1
- Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04753216Phase 2Results posted
- Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerCompletedNCT03785873Phase 1/2Results posted
- Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerActive, not recruitingNCT03337087Phase 1/2Results posted
- BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent GlioblastomaTerminatedNCT03119064Phase 1/2Results posted
- Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerCompletedNCT03088813Phase 3Results posted
- Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaCompletedNCT02551991Phase 2Results posted
- MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentCompletedNCT01770353Phase 1Results posted
- Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic CancerCompletedNCT01494506Phase 3Results posted
- A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLCCompletedNCT06478043Phase 2
- Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the PancreasCompletedNCT06225999Phase 2
- A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the PancreasCompletedNCT05383352Phase 1
- Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal CancerActive, not recruitingNCT05277766Phase 1
- A Study of Irinotecan Hydrochloride Liposome in Advanced Solid TumorsCompletedNCT05086822Phase 1
- Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaStatus unknownNCT05047991Phase 2
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT04752696Phase 2
- Study of Irinotecan Liposome Injection in Patients With Advanced Breast CanceCompletedNCT04728035Phase 1
- Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)CompletedNCT04727853Phase 2
- Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid TumorsStatus unknownNCT04569916Phase 2
- Phase I Trial HIPEC With Nal-irinotecanCompletedNCT04088786Phase 1
- Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver MetastasesWithdrawnNCT04037241Phase 2/3
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerActive, not recruitingNCT04005339Phase 2
- Second Line Treatment With Nal-IRI and S1 in Pancreatic CancerStatus unknownNCT03986294Phase 2
- Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid TumorsCompletedNCT03810742Phase 1
- SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell CancerStatus unknownNCT03732508Phase 2
- Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell CarcinomaCompletedNCT03719924Phase 2
- Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or ChemoradiotherapyCompletedNCT03712397Phase 2
- First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRICompletedNCT03693677Phase 2
- A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic CancerStatus unknownNCT03528785Phase 2
- Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract CancerCompletedNCT03524508Phase 2
- First-line Therapy in Metastatic PDACStatus unknownNCT03487016Phase 2
- 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line TherapyCompletedNCT03468335Phase 3
- TAS102 in Combination With NAL-IRI in Advanced GI CancersActive, not recruitingNCT03368963Phase 1/2
- Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer PatientsCompletedNCT03328884Phase 2
- Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With CachexiaCompletedNCT03207724Phase 1
- CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)CompletedNCT03086616Phase 1
- Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based TherapiesCompletedNCT03043547Phase 2
- A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid TumorsCompletedNCT02884128Phase 1
- Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal CancerWithdrawnNCT02785068Phase 1/2
- Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic CancerCompletedNCT02697058Phase 2
- A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced CancerCompletedNCT02640365Phase 1
- Liposomal Irinotecan and Veliparib in Treating Patients With Solid TumorsCompletedNCT02631733Phase 1
- Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade GliomaCompletedNCT02022644Phase 1
- Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base TherapyCompletedNCT00940758Phase 1
- Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic CancerCompletedNCT00813163Phase 2
- Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT00813072Phase 2